suramin has been researched along with Ache in 18 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Using a fixed higher-dose schedule, the efficacy and toxicity of suramin plus hydrocortisone were assessed in patients with metastatic hormone-refractory prostate carcinoma (HRPC)." | 9.09 | Fixed higher dose schedule of suramin plus hydrocortisone in patients with hormone refractory prostate carcinoma a multicenter Phase II study. ( Beltrán, C; Berián, JM; Brugarolas, A; Calvo, E; Cortés, J; de Irala, J; Martínez-Monge, R; Rebollo, J; Rodríguez, J; Sureda, M, 2001) |
| "Overall mean reductions in combined pain and opioid analgesic intake were greater for suramin plus HC (rank sum P =." | 5.09 | Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. ( Chen, L; Eisenberger, M; Lenehan, PF; Marshall, ME; Meyer, M; Meyers, FJ; Natale, RB; Reyno, LM; Slichenmyer, WJ; Small, EJ, 2000) |
| "Using a fixed higher-dose schedule, the efficacy and toxicity of suramin plus hydrocortisone were assessed in patients with metastatic hormone-refractory prostate carcinoma (HRPC)." | 5.09 | Fixed higher dose schedule of suramin plus hydrocortisone in patients with hormone refractory prostate carcinoma a multicenter Phase II study. ( Beltrán, C; Berián, JM; Brugarolas, A; Calvo, E; Cortés, J; de Irala, J; Martínez-Monge, R; Rebollo, J; Rodríguez, J; Sureda, M, 2001) |
| " As a result, mitoxantrone plus prednisone has been demonstrated to be a useful palliative therapy that provides improvements in pain and quality of life for approximately 40% of those treated." | 4.81 | Treatment of hormone refractory prostate cancer. ( Knox, JJ; Moore, MJ, 2001) |
| " In order to determine if the endogenous opioid system is involved in this antinociception, naloxone was administered just prior to the injection of a selective P2X3/P2X2/3 receptor antagonist, A-317491, in rat models of neuropathic, chemogenic, and inflammatory pain." | 3.73 | Endogenous opioid mechanisms partially mediate P2X3/P2X2/3-related antinociception in rat models of inflammatory and chemogenic pain but not neuropathic pain. ( Bianchi, B; Faltynek, CR; Honore, P; Jarvis, MF; McDonald, HA; McGaraughty, S; Mikusa, J; Wismer, CT; Zhu, CZ, 2005) |
| "Vortex keratopathy occurred in six patients given high-dose intravenous suramin for adrenocortical carcinoma." | 3.67 | Suramin keratopathy. ( Chan, CC; Holland, EJ; Kuwabara, T; LaRocca, R; McAtee, N; Myers, CE; Nussenblatt, RN; Palestine, AG; Stein, CA; Thomas, R, 1988) |
| "Suramin has limited, but significant, efficacy even in chemotherapy- and hormone-refractory prostate cancer, without serious toxicity." | 2.69 | Suramin treatment in hormone- and chemotherapy-refractory prostate cancer. ( Allolio, B; Garcia-Schürmann, JM; Haupt, G; Pastor, J; Schulze, H; Senge, T, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (11.11) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 11 (61.11) | 29.6817 |
| 2010's | 4 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, HP | 1 |
| Li, CL | 1 |
| Lu, P | 1 |
| Zheng, JC | 1 |
| Yu, LL | 1 |
| Yang, WM | 1 |
| Xiong, F | 1 |
| Zeng, XY | 1 |
| Li, N | 1 |
| Lu, ZY | 1 |
| Yu, LH | 1 |
| Burnstock, G | 1 |
| Deng, XM | 1 |
| Ma, B | 1 |
| Ren, C | 1 |
| Gan, X | 1 |
| Wu, J | 1 |
| Qiu, CY | 1 |
| Hu, WP | 1 |
| Ballok, DA | 1 |
| Sakic, B | 1 |
| Atkinson, TM | 1 |
| Halabi, S | 1 |
| Bennett, AV | 1 |
| Rogak, L | 1 |
| Sit, L | 1 |
| Li, Y | 1 |
| Kaplan, E | 1 |
| Basch, E | 1 |
| KONOW, V | 1 |
| Joseph, EK | 1 |
| Chen, X | 1 |
| Khasar, SG | 1 |
| Levine, JD | 1 |
| McGaraughty, S | 1 |
| Honore, P | 2 |
| Wismer, CT | 1 |
| Mikusa, J | 2 |
| Zhu, CZ | 1 |
| McDonald, HA | 1 |
| Bianchi, B | 2 |
| Faltynek, CR | 1 |
| Jarvis, MF | 2 |
| Garcia-Schürmann, JM | 1 |
| Schulze, H | 1 |
| Haupt, G | 1 |
| Pastor, J | 1 |
| Allolio, B | 1 |
| Senge, T | 1 |
| Small, EJ | 2 |
| Meyer, M | 2 |
| Marshall, ME | 1 |
| Reyno, LM | 1 |
| Meyers, FJ | 1 |
| Natale, RB | 1 |
| Lenehan, PF | 2 |
| Chen, L | 2 |
| Slichenmyer, WJ | 2 |
| Eisenberger, M | 2 |
| Masaki, E | 1 |
| Ebisawa, T | 1 |
| Kondo, I | 1 |
| Hayashida, K | 1 |
| Matsumoto, Y | 1 |
| Kawamura, M | 1 |
| Fukuhara, N | 1 |
| Imai, Y | 1 |
| Sakakibara, A | 1 |
| Morita, K | 1 |
| Kitayama, S | 1 |
| Tanne, K | 1 |
| Dohi, T | 1 |
| McMillan, A | 1 |
| Knox, JJ | 1 |
| Moore, MJ | 1 |
| Calvo, E | 1 |
| Cortés, J | 1 |
| Rodríguez, J | 1 |
| Sureda, M | 1 |
| Beltrán, C | 1 |
| Rebollo, J | 1 |
| Martínez-Monge, R | 1 |
| Berián, JM | 1 |
| de Irala, J | 1 |
| Brugarolas, A | 1 |
| Yoshida, K | 1 |
| Nakagawa, T | 1 |
| Kaneko, S | 1 |
| Akaike, A | 1 |
| Satoh, M | 1 |
| McDonald, H | 1 |
| Cartmell, J | 1 |
| Faltynek, C | 1 |
| Holland, EJ | 1 |
| Stein, CA | 1 |
| Palestine, AG | 1 |
| LaRocca, R | 1 |
| Chan, CC | 1 |
| Kuwabara, T | 1 |
| Myers, CE | 1 |
| Thomas, R | 1 |
| McAtee, N | 1 |
| Nussenblatt, RN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study of Oral Calcitriol in Combination With Ketoconazole in Castration Resistant Prostate Cancer, Progressing Despite Primary ADT and Abiraterone[NCT03261336] | Phase 2 | 1 participants (Actual) | Interventional | 2017-01-06 | Terminated (stopped due to can not meet enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Descriptive analysis of observed toxicity and patient reports of tolerating experimental treatment (NCT03261336)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Calcitriol, Ketoconazole, Hydrocortisone | 1 |
1 review available for suramin and Ache
| Article | Year |
|---|---|
Treatment of hormone refractory prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Est | 2001 |
5 trials available for suramin and Ache
| Article | Year |
|---|---|
Measurement of affective and activity pain interference using the Brief Pain Inventory (BPI): Cancer and Leukemia Group B 70903.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Factor Analysis, Statistical; | 2012 |
Suramin treatment in hormone- and chemotherapy-refractory prostate cancer.
Topics: Aged; Analgesia; Antineoplastic Agents; Humans; Male; Middle Aged; Pain; Prostatic Neoplasms; Surami | 1999 |
Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Dise | 2000 |
Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival.
Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Biomarkers, Tumor; Dis | 2001 |
Fixed higher dose schedule of suramin plus hydrocortisone in patients with hormone refractory prostate carcinoma a multicenter Phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease Progress | 2001 |
12 other studies available for suramin and Ache
| Article | Year |
|---|---|
The function of P2X3 receptor and NK1 receptor antagonists on cyclophosphamide-induced cystitis in rats.
Topics: Animals; Cyclophosphamide; Cystitis; Disease Models, Animal; Female; Neurokinin-1 Receptor Antagonis | 2014 |
Inhibition of G protein-coupled P2Y2 receptor induced analgesia in a rat model of trigeminal neuropathic pain.
Topics: Action Potentials; Animals; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Dru | 2014 |
Enhancement of acid-sensing ion channel activity by metabotropic P2Y UTP receptors in primary sensory neurons.
Topics: Acid Sensing Ion Channels; Acidosis; Adenosine Diphosphate; Adenosine Triphosphate; Animals; Dose-Re | 2016 |
Purine receptor antagonist modulates serology and affective behaviors in lupus-prone mice: evidence of autoimmune-induced pain?
Topics: Analysis of Variance; Animals; Anxiety; Autoantibodies; Autoimmunity; Body Weight; Cell Shape; Dendr | 2008 |
[Muscular pain following succinylcholine administration; trail of control by germanin (Bayer 205)].
Topics: Disease; Humans; Muscles; Muscular Diseases; Pain; Succinylcholine; Suramin | 1959 |
Novel mechanism of enhanced nociception in a model of AIDS therapy-induced painful peripheral neuropathy in the rat.
Topics: Aminoquinolines; Animals; Anti-HIV Agents; Antineoplastic Agents; Behavior, Animal; Calcium Channel | 2004 |
Endogenous opioid mechanisms partially mediate P2X3/P2X2/3-related antinociception in rat models of inflammatory and chemogenic pain but not neuropathic pain.
Topics: Analgesia; Animals; Arthritis, Experimental; Dose-Response Relationship, Drug; Endorphins; Formaldeh | 2005 |
P2-purinergic receptor antagonists reduce the minimum alveolar concentration of inhaled volatile anesthetics.
Topics: Adenosine Triphosphate; Anesthesia; Anesthetics, Inhalation; Animals; Antineoplastic Agents; Brain; | 2000 |
Regulation of the development of allodynia by intrathecally administered P2 purinoceptor agonists and antagonists in mice.
Topics: Adenosine Triphosphate; Animals; Dinoprostone; Dizocilpine Maleate; Injections, Spinal; Male; Mice; | 2000 |
Adenosine 5'-triphosphate inhibits slow depolarization induced by repetitive dorsal root stimulation via P2Y purinoceptors in substantia gelatinosa neurons of the adult rat spinal cord slices with the dorsal root attached.
Topics: Action Potentials; Adenosine Triphosphate; Animals; Dose-Response Relationship, Drug; Electric Stimu | 2002 |
TNP-ATP, a potent P2X3 receptor antagonist, blocks acetic acid-induced abdominal constriction in mice: comparison with reference analgesics.
Topics: Abdomen; Acetic Acid; Adenosine Triphosphate; Analgesics; Animals; Antineoplastic Agents; Behavior, | 2002 |
Suramin keratopathy.
Topics: Adrenal Cortex; Adrenal Gland Neoplasms; Adult; Carcinoma; Corneal Diseases; Female; Humans; Injecti | 1988 |